Charles River Laboratories International (CRL) Cost of Revenue (2009 - 2025)

Charles River Laboratories International (CRL) has reported Cost of Revenue for 17 consecutive years, with $249.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cost of Revenue fell 81.75% year-over-year to $249.3 million; the TTM figure through Dec 2025 stood at $1.8 billion (down 27.18% YoY), while the FY2025 annual figure was $576.2 million, down 66.05% from the prior year.
• Cost of Revenue came in at $249.3 million for Q4 2025 at Charles River Laboratories International, down from $408.1 million in the prior quarter.
• The five-year high for Cost of Revenue was $1.4 billion in Q4 2024, with the low at -$1.0 billion in Q4 2021.
• Average Cost of Revenue over 5 years is $396.2 million, with a median of $455.4 million recorded in 2021.
• Across the five-year window, Cost of Revenue soared 653.48% in 2023 and sank 81.75% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at -$1.0 billion in 2021, then jumped by 160.23% to $603.1 million in 2022, then sank by 47.19% to $318.5 million in 2023, then soared by 328.74% to $1.4 billion in 2024, then tumbled by 81.75% to $249.3 million in 2025.
• According to Business Quant data, Cost of Revenue over the past three periods registered $249.3 million, $408.1 million, and $584.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.